Clinical Trials on Alzheimer Disease in Austria

Total 17311 results

Affiris AG

Completed

AD01 Follow up Extension Visit

Alzheimer´s Disease

Austria
Washington University School of Medicine
Hoffmann-La Roche; National Institute on Aging (NIA); Alzheimer's Association

Terminated

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, France, Spain, Ireland, Canada, Australia, Puerto Rico, United Kingdom
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Completed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, France, Spain, Ireland, Australia, Puerto Rico, United Kingdom
Affiris AG

Terminated

Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease

Alzheimer´s Disease

Austria
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, France, Ireland, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom, Brazil, Japan, Germany
Medical University of Graz
Joanneum Research Forschungsgesellschaft mbH; Sozialverein Deutschlandsberg... and other collaborators

Unknown

Playful Multimodal Intervention, Monitoring and Decision Support for Activation of People With Alzheimer's Dementia (M-AAL)

Alzheimer Disease

Austria
Washington University School of Medicine
National Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)

Alzheimers Disease

United States, United Kingdom, Korea, Republic of, Poland, Canada, Australia, Argentina, Spain, Sweden, Italy
reMYND
NeuroScios GmbH

Completed

A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127

Alzheimer Disease

Austria
Affiris AG

Completed

Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Austria
Affiris AG

Completed

Long-term Safety and Tolerability of AFFITOPE AD01

Alzheimer's Disease

Austria
Affiris AG

Completed

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

Alzheimer's Disease

Austria
Affiris AG

Completed

Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Austria
Storz Medical AG
Medical University of Vienna

Completed

Brain Stimulation for Neurological Patients

Alzheimer Disease

Austria
Ever Neuro Pharma GmbH

Withdrawn

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) (DAT)

Alzheimer Disease

Austria
Affiris AG

Completed

Safety and Tolerability of AFFITOPE AD03 (MimoVax)

Alzheimer's Disease

Austria
Affiris AG

Completed

Long-term Safety and Tolerability of AFFITOPE AD02

Alzheimer's Disease

Austria
Washington University School of Medicine
Hoffmann-La Roche; Genentech, Inc.; National Institute on Aging (NIA); Alzheimer...

Suspended

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, France, Spain, Ireland, Argentina, Australia, Colombia, Germany, Mexico, Netherlands, Puerto Rico, United Kingdom
Affiris AG

Terminated

Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A

Alzheimer's Disease

Austria
Hoffmann-La Roche

Recruiting

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

Korea, Republic of, United States, Canada, Poland, Spain, Australia, Japan, Chile, United Kingdom
Axon Neuroscience SE

Completed

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (FUNDAMANT)

Alzheimer's Disease

Austria
Axon Neuroscience SE

Completed

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Alzheimer Disease

Austria
Medical University of Vienna

Recruiting

Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease

Healthy | Alzheimer Disease | Mild Cognitive Impairment

Austria
Novartis Pharmaceuticals
National Institute on Aging (NIA); Amgen; Banner Alzheimer's Institute

Terminated

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)

Alzheimers Disease

United States, Belgium, United Kingdom, Germany, Australia, Canada, Spain, Finland, Switzerland, Netherlands
University of South Australia
Flinders University

Recruiting

Small Steps Towards Improving Activity and Sleep Habits to Decrease the Risk of Dementia

Dementia | Alzheimer Disease

Australia
SciNeuro

Completed

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

Neurodegenerative Diseases | Alzheimer's Disease

Australia
Cerecin

Terminated

Tricaprilin Liquid Formulation PK Study

Alzheimer Disease

Australia
H. Lundbeck A/S

Terminated

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Alzheimer Disease

Austria, Finland, Sweden
Novartis Pharmaceuticals
Amgen; Banner Alzheimer's Institute

Terminated

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2)

Alzheimers Disease

Spain, United States, Belgium, Italy, Germany, Australia, Israel, Taiwan, Japan, Canada, Korea, Republic of, United Kingdom, France, China, Argentina, Finland, Singapore, Portugal, Chile, Mexico, Switzerland, Netherlands, Iceland, Puerto... and more
Neuroscience Trials Australia
The Florey Institute of Neuroscience and Mental Health

Active, not recruiting

Deferiprone to Delay Dementia (The 3D Study)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's Disease

Australia
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults

Healthy | Alzheimer Disease | Gastric Retention

Australia
Inventage Lab., Inc.

Recruiting

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

Alzheimer Disease

Australia
Seelos Therapeutics, Inc.

Withdrawn

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease ([STRIVE-AD])

Alzheimer's Disease

Australia
Anavex Life Sciences Corp.

Completed

An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Australia
Anavex Life Sciences Corp.

Completed

Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (ANAVEX)

Alzheimer's Disease

Australia
Asceneuron Pty Ltd.
Neuroscience Trials Australia; Asceneuron S.A.

Terminated

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

Alzheimer Disease

Australia
Cerecin

Completed

Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

Alzheimer Disease

Australia
Debiopharm International SA

Completed

Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease (BRAINz)

Moderate Alzheimer's Disease

Australia, Canada, United Kingdom
Cerecin

Completed

AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions

Alzheimer Disease

Australia
Cerecin

Completed

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Alzheimer Disease

Australia
VTBIO Co. LTD
BHT Lifescience Austrailia Pty Ltd.

Unknown

A Safety and Tolerability Study of GB301

Alzheimer Disease

Australia
Affiris AG

Terminated

Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006

Alzheimer´s Disease

France, Austria, Croatia, Czech Republic, Germany, Slovakia
Atridia Pty Ltd.

Recruiting

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease (AD)

Australia
Atridia Pty Ltd.

Completed

A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects

Alzheimer Disease

Australia
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

Alzheimer's Disease

Australia
Athira Pharma
National Institute on Aging (NIA)

Completed

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease (ACT-AD)

Alzheimer Disease | Dementia of Alzheimer Type

United States, Australia
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
Bristol-Myers Squibb

Completed

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Florbetapir Calibration to the Centiloid Scale

Alzheimer's Disease

United States, Australia
Baxalta now part of Shire

Terminated

Phase 3 IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States, Poland, United Kingdom, Belgium, Spain, Japan, Canada, Australia

Clinical Trials on Alzheimer Disease in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations